Company Analysis
Sign in

Inhibrx Biosciences, Inc. (INBX)

Nasdaq: INBX · Biological Products, (No Diagnostic Substances) · La Jolla, CA · filing with the SEC since 2024
Full chart Alerts Compare
Grade4.5
◀ Past 5.2● Present 4.2▶ Future 4.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Inhibrx Biosciences, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.5/10
◀ Past5.225% of the headline
● Present4.235% of the headline
▶ Future4.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.2/1025% of the headline grade · 3 of 3 filed

Surviving crises

as filed
8.0/10

Has it survived what it has been through?

No warning events in its filings since 2024.

weight 22% of this tense · 80th percentile among 159 sector filers · read for itself

From the record

Inhibrx Biosciences, Inc.'s filings since 2024 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.5/10

What has it actually done, year after year?

-15% a year over 3 filed years; profitable in 1 of 3.

weight 45% of this tense · 45th percentile among 102 sector filers · read for its customers

From the record

Inhibrx Biosciences, Inc.'s 3 filed years say what it did: revenue went from $2 million in fiscal 2023 to $1 million in fiscal 2025, down 15% a year; it rose in 1 of 2 years; the deepest fall was 89% from fiscal 2023 to fiscal 2024; net income was positive in 1 of 3 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-15.0%bottom 14% of its family
  • the share of years revenue rosebottom 42% of its family
  • the share of filed years with a profittop 15% of its family
  • the deepest fall from a revenue peak88.9%bottom 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed
4.2/10

How has it treated the people who own it?

Share count grew 14.6% a year. 0% of cash flow returned. Insiders: 5 sales, 20 purchases.

weight 33% of this tense · 42nd percentile among 21 sector filers · read for its shareholders

From the record

Over the 2 fiscal years to 2025-12-31, Inhibrx Biosciences, Inc.'s diluted share count grew about 14.6% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 5 sales and 20 purchases of their own stock on the open market in the year to 2026-10-14, buying about $6 million (their Form 4 filings).

What it rests on

  • the share count over the yearstop 40% of its family
  • cash returned against operating cash flowbottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

4.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.3/10

Is it financially healthy right now?

ROE -1752%: lost 1752¢ per shareholder dollar. Leverage 95%: owes 95¢ per asset dollar.

weight 45% of this tense · 33rd percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Inhibrx Biosciences, Inc. lost about 1752 cents for every dollar of shareholders' money. Leverage: it owed about 95 cents per dollar of assets, and net share issuance: its share count grew 3.4% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 19% of its family
  • return on equitybottom 1% of its family
  • the share count against the year beforetop 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
2.0/10

How strong is its position in its industry?

bottom 20% of 102 in its family; net margin -10773.5%.

weight 22% of this tense · 20th percentile among 102 sector filers · read for its customers

From the record

Inhibrx Biosciences, Inc.'s standing among 102 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 20% by size; a net margin of -10773.5% ranks in the bottom 14%; revenue growth of -15% a year over the last 2 filed years ranks in the bottom 27% (its annual reports).

What it rests on

  • revenue against the family$1.3Mbottom 20% of its family
  • net margin-10773.5%bottom 14% of its family
  • three-year revenue growth-15.0%bottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
7.0/10

What are the people in charge doing?

SI estimate 7.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 70th percentile among 137 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 30% of 137 in its family; the record of its people begins on 2024-05-24 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.5 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2024-05-24 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.5 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 137 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Inhibrx Biosciences, Inc.'s leadership is put at 7.0 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 30% of 137 in its family; the record of its people begins on 2024-05-24 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.5 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
4.3/10

How much room does it have to grow?

bottom 43% of 92 in its family for room to expand.

weight 33% of this tense · 43rd percentile among 92 sector filers · read for itself

From the record

Inhibrx Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $124 million against debt of $101 million leaves 16.2% of its assets as net cash, bottom 27% of its family; cash from operations less capital spending is -9986.5% of revenue (bottom 8%); research spending of 8694.5% of revenue (top 7%) (its annual report).

What it rests on

  • cash less debt against assets16.2%bottom 27% of its family
  • cash from operations less capital spending against revenue-9986.5%bottom 8% of its family
  • research spending against revenue8694.5%top 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.2/10

What could actually drive growth from here?

bottom 42% of 100 in its family for growth drivers.

weight 45% of this tense · 42nd percentile among 100 sector filers · read for its customers

From the record

Inhibrx Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -15% a year over the last three filed years against -15% over all 3, speeding up (top 36% of its family); the newest year grew 550.8% (top 6%); research spending grew -23.2% a year (bottom 10%); capital spending grew -91.8% a year (bottom 2%) (its annual reports). Inhibrx Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 36% of its family
  • the newest year's revenue growth550.8%top 6% of its family
  • three-year growth of research spending-23.2%bottom 10% of its family
  • three-year growth of capital spending-91.8%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 73 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 73 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Inhibrx Biosciences, Inc.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton INBX · research, not advice